ArticleAmerican journal of translational research2026
Tofacitinib demonstrates favorable efficacy but an increased risk of herpes zoster in elderly patients with rheumatoid arthritis: a retrospective cohort analysis.
Article in American journal of translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy of tofacitinib in elderly patients with rheumatoid arthritis (RA) and analyze herpes zoster risk factors.
methodsA retrospective analysis included elderly RA patients from January 2022 to June 2024. Patients were assigned to a tofacitinib group (n=62, tofacitinib + methotrexate) or a conventional disease-modifying antirheumatic drugs (DMARDs) group (n=58, methotrexate + leflunomide). Clinical efficacy, inflammatory markers, American College of Rheumatology (ACR) response rates, joint function, herpes zoster incidence, and other adverse reactions were assessed.
resultsAfter treatment, the tofacitinib group had lower Disease Activity Score 28-erythrocyte sedimentation rate (ESR) scores than the conventional DMARDs group (P<0.05). ESR, C-reactive protein, and rheumatoid factor levels were significantly lower (P<0.05), while ACR20/50/70 response rates were significantly higher in the tofacitinib group (P<0.05). Health Assessment Questionnaire Disability Index scores, morning stiffness duration, and pain scores were also lower (P<0.05). Herpes zoster incidence was higher in the tofacitinib group (12.90%) than that in the conventional DMARDs group (3.45%; P<0.05). Multivariable logistic regression identified tofacitinib use, age ≥75 years, glucocorticoid use, reduced lymphocyte count, and prior herpes zoster as independent risk factors (P<0.05).
conclusionsTofacitinib is efficacious in elderly RA patients, improving disease activity and joint function, but increases herpes zoster risk. High-risk patients require monitoring; prophylactic vaccination may be considered.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.